ARTICLE | Clinical News
Iclusig ponatinib: Phase II started
September 28, 2015 7:00 AM UTC
Ariad began the open-label, international Phase II OPTIC trial to evaluate 15, 30 and 45 mg oral Iclusig once daily in about 450 patients who are resistant to >=2 approved TKIs. Patients in the 2 higher dose arms will have their dose reduced to 15 mg upon achievement of MyCyR. ...